Increased peripheral expansion of naive CD4+ T cellsin vivoafter IL-2 treatment of patients with HIV infection
Open Access
- 29 July 2002
- journal article
- clinical trial
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (16) , 10712-10717
Abstract
Intermittent interleukin-2 (IL-2) therapy has been shown to increase the number of CD4+ T cells, preferentially cells with a naive phenotype, in patients with HIV infection. For this report we investigated the mechanism underlying this expansion by studying the relative roles of peripheral expansion and thymic output. In a cohort of six patients receiving IL-2 over a period of 1 year, the mean number of naive CD4+ T cells increased from 139 to 387 cells per μl while levels of T cell receptor rearrangement excision circles (TRECs) declined from 47,946 to 26,510 copies per 106naive T cells, thus making it unlikely that the CD4+ T cell count increases were secondary to increase in thymic output. To examine directly the impact of IL-2 on peripheral expansion, peripheral blood mature, naive CD4+ T cells were labeledex vivowith 5-bromodeoxyuridine as well as stained directly for Ki67. These studies revealed a 7-fold increase in the percentage of 5-bromodeoxyuridine-positive cells and a 20–40-fold increase in Ki67 staining in the naive CD4+ T cell pool in the setting of IL-2 administration. This degree of increase in mature CD4+ T cell turnover induced by IL-2 does not compromise the future replicative potential of these cells, because longitudinal measurements of telomere length went from 6,981 to 7,153 bp after 1 year of IL-2 therapy. These data strongly suggest that much of the increase in CD4+ cells associated with IL-2 treatment is caused by peripheral expansion of existing naive CD4+ T cells rather than increased thymic output and that these increases occur without compromising the potential of these cells for further cell division.Keywords
This publication has 30 references indexed in Scilit:
- Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patientsAIDS, 2001
- Immunopathogenesis of Human Immunodeficiency Virus: Implications for Immune‐Based TherapiesClinical Infectious Diseases, 2001
- Evaluation of T Cell Receptor Gene Rearrangement Excision Circles after Antiretroviral Therapy in Children Infected with Human Immunodeficiency VirusThe Journal of Infectious Diseases, 2001
- Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapyEuropean Journal of Immunology, 2001
- The Role of the Thymus in Immune Reconstitution in Aging, Bone Marrow Transplantation, and HIV-1 InfectionAnnual Review of Immunology, 2000
- Outpatient Continuous Intravenous Interleukin‐2 or Subcutaneous, Polyethylene Glycol‐Modified Interleukin‐2 in Human Immunodeficiency Virus‐Infected Patients: A Randomized, Controlled, Multicenter StudyThe Journal of Infectious Diseases, 1998
- Telomere dynamics in HIV‐1 infected and uninfected chimpanzees measured by an improved method based on high‐resolution two‐dimensional calibration of DNA sizesJournal of Medical Primatology, 1998
- T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4 + T Cell TurnoverScience, 1996
- Antigen-independent activation of naive and memory resting T cells by a cytokine combination.Journal of Experimental Medicine, 1994
- Telomeres shorten during ageing of human fibroblastsNature, 1990